SUBSCRIBERS


Why a free subscription?
Forgotten your password?
I subscribe
SERVICES
Library
Video library
RSS feed
----------------------------------
Useful links
Your comments
Membre de la FFAP
Active member of the French Federation of Press Agencies
Add to Google
Add to Yahoo
Add to Netvibes
http://www.wikio.fr

Website created by NetStudio

Article



Dépêche Destination Santé Meningitis – Africa awaits a new vaccine

[22 June 2007 - 08:54]

Meningitis epidemics are regular if unwelcome visitors to Africa but now officials from the Meningitis Vaccine Project (the MVP) are reporting promising results from a new phase II clinical trial. This relates to a new candidate vaccine of the conjugate type.

Effective, safe and costing only 0.4 dollars per dose, this new vaccine could be introduced in Africa within 3 to 4 years. Directed against the N. Meningitidis A meningococcal strain, “it could enable us to put an end to the epidemics that have ravaged Africa for more than 100 years”, points out MVP director Dr Marc Laforce.

Experts talk of an African meningitis belt – an area stretching from west to east, from Senegal to Ethiopia. “During the dry season”, the WHO tells us, “because of the dust-laden winds and the high number of respiratory tract infections contracted, local immunity of the pharynx is diminished, thus increasing the risk of meningitis”. In fact, in 1996 the WHO reported over 250,000 cases of meningitis and 25,000 deaths. The most deadly meningitis epidemic ever!

At present healthcare professionals are using a vaccine that gives immunity for only 3 to 5 years. A vaccine which, according to the WHO, cannot be used on children under 2 years old. According to Dr Laforce, “the population from the ages of 1 to 29 could be immunised by receiving a single dose of the new vaccine. Results show that we could create a collective immunity, as this would block transmission of the bacterium. This would mean that the protection would be extended to those who were not vaccinated”. Clinical trials of phases 2 and 3 are planned in Mali and another trial will be launched this summer in India. The license for this new vaccine belongs to the Serum Institute of India Limited..

Cet article est aussi disponible en français

Source : Meningitis Vaccine Project, WHO 7 June 2007 – Aide mémoire No.141, WHO May 2003

 
Imprimer cette dépêche
Consulter au format PDF
Envoyer le lien à un ami
 
Print
this article
Convert to
PDF
Send
this article
Copyright
Authorization
LAST PUBLICATION
8 article(s) in this heading